ReviewFuture microbiology2013
The RTX pore-forming toxin α-hemolysin of uropathogenic Escherichia coli: progress and perspectives.
Review in Future microbiology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 1 synthesis or guideline pooled it, 89 citations in OpenAlex.
- Prevalence of bovine endometritis, virulence mechanisms ofVirulence · 2026Pooled it
- Review
- Genetic variability of Shiga toxin-producingMicrobiology spectrum · 2025Article
- The Role ofInternational journal of molecular sciences · 2025Review
- LDL receptor-mediated endocytosis ofProceedings of the National Academy of Sciences of the United States of America · 2025Article
- High Efficacy of Rose Bengal in Reducing the Pathogenicity ofInternational journal of microbiology · 2025Article
- Transcriptional profiling ofFrontiers in cellular and infection microbiology · 2025Article
- Overview of Bacterial Protein Toxins from Pathogenic Bacteria: Mode of Action and Insights into Evolution.Toxins · 2024Review
- Article
- D-Serine reduces the expression of the cytopathic genotoxin colibactin.Microbial cell (Graz, Austria) · 2023Article
- Characterization ofFrontiers in microbiology · 2023Article
- Epidemiology and characterization ofAccess microbiology · 2023Article
- Genotypic characteristics of UropathogenicPeerJ · 2023Article
- Evaluation of the Pathogenic Potential ofMicroorganisms · 2022Article
- Bacterial pore-forming toxins.Microbiology (Reading, England) · 2022Article
- Review
- Interactive Dynamics of Cell Volume and Cell Death in Human Erythrocytes Exposed to α-Hemolysin fromInternational journal of molecular sciences · 2022Article
- Article
- Comparative Pathogenomics ofInfection and immunity · 2021Article
- Bacterial Toxins Are a Never-Ending Source of Surprises: From Natural Born Killers to Negotiators.Toxins · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Members of the RTX family of protein toxins are functionally conserved among an assortment of bacterial pathogens. By disrupting host cell integrity through their pore-forming and cytolytic activities, this class of toxins allows pathogens to effectively tamper with normal host cell processes, promoting pathogenesis. Here, we focus on the biology of RTX toxins by describing salient properties of a prototype member, α-hemolysin, which is often encoded by strains of uropathogenic Escherichia coli. It has long been appreciated that RTX toxins can have distinct effects on host cells aside from outright lysis. Recently, advances in modeling and analysis of host-pathogen interactions have led to novel findings concerning the consequences of pore formation during host-pathogen interactions. We discuss current progress on longstanding questions concerning cell specificity and pore formation, new areas of investigation that involve toxin-mediated perturbations of host cell signaling cascades and perspectives on the future of RTX toxin investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.